The effect of CDK4 inhibitor to AML

被引:0
|
作者
wang, Jie [1 ]
机构
[1] Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA
来源
关键词
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
引用
收藏
页码:62 / 62
页数:1
相关论文
共 50 条
  • [21] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
    Sorrentino, J.
    Bisi, J.
    Thompson, D.
    Lai, A.
    Strum, J.
    Roberts, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E47 - E48
  • [24] FDA approves Novartis's CDK4/6 inhibitor
    Mullard A.
    Nature Reviews Drug Discovery, 2017, 16 (4) : 229 - 229
  • [25] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [26] FDA approves Novartis's CDK4/6 inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (04) : 229 - 229
  • [27] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [29] Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
    van Aken, Evert S. M.
    Beeker, Aart
    Houtenbos, Ilse
    Pos, Floris J.
    Linn, Sabine C.
    Elkhuizen, Paula H. M.
    de Jong, Monique C.
    CANCER REPORTS, 2022, 5 (02)
  • [30] Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
    Wander, Seth A.
    Bardia, Aditya
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2008 - 2010